ArticleAnimal biotechnology2025
Enhanced susceptibility of porcine muscle-derived mesenchymal stem cells to Aujeszky's virus compared Vero cells.
Article in Animal biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cells (MSCs) can self-renew and differentiate into several lineages and can be isolated from different tissues such as bone marrow, adipose tissue, umbilical cord blood, and muscle. Herein, we established MSCs derived from miniature pig muscle (MpMu-MSCs) and assessed their response to Aujeszky's virus. We characterized the MpMu-MSCs based on their cellular morphology, proliferation properties, cell surface marker expression, and mesodermal differentiation potential. MpMu-MSCs demonstrated a fibroblast-like spindle shape and formed a homogeneous monolayer. They showed a considerable increase in cell proliferation over 16 passages. The cells expressed surface markers CD29, CD44, CD90, and CD105 and demonstrated mesodermal lineage differentiation capabilities. MpMu-MSCs demonstrated faster cytopathic effects than the Vero cells when infected with Aujeszky's virus. The virus titer in MpMu-MSCs was initiated at 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.